綠葉製藥(02186.HK)向金賽藥業授予阿爾茨海默病透皮貼劑中國獨家商業化權利
綠葉製藥(02186.HK)公布,與長春金賽藥業訂立協議,向其授予利斯的明透皮貼劑(單日貼)和利斯的明透皮貼劑(多日貼)在中國的獨家商業化權利。
根據協議,綠葉瑞士授予金賽藥業在協議地區進口、銷售、推廣、營銷與使用利斯的明透皮貼劑(單日貼)和利斯的明透皮貼劑(多日貼)的獨家不可轉讓的、可分許可的永久商業化權利。而綠葉瑞士繼續持有該產品在協議地區的資產權、註冊准證等商業化以外的權利。
金賽藥業將在相關協議簽署後向綠葉瑞士支付首付款7,000萬元人民幣,協議總交易金額最高達2.16億元人民幣。
利斯的明透皮貼劑用於治療輕、中度阿爾茨海默病的症狀,由綠葉集團在歐洲的透皮釋藥技術平台開發和生產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.